Most people assume that pregnant women with opioid use disorder have limited treatment options, but this groundbreaking study challenges that notion. You need to know about this randomised clinical trial involving 140 pregnant adults conducted at 13 outpatient sites between 2020 and 2024. The research directly compared weekly extended-release buprenorphine injections against the standard sublingual formulation – and the results could change how we approach opioid addiction treatment during pregnancy and beyond.
Key Takeaways:
- A pregnant woman struggling with opioid use disorder faces tough choices about treatment – and this study just made one of those choices a lot clearer. Weekly extended-release buprenorphine injections actually worked better than daily sublingual buprenorphine during pregnancy, with women staying off illicit opioids 82.5% of the time compared to 72.6% with the sublingual version. That’s a real difference that could change lives. The study followed 140 pregnant women through delivery and a full year after giving birth, and what they found was pretty compelling. During pregnancy, that weekly shot meant fewer relapses and fewer serious health problems for moms – only 8.7% had serious adverse events compared to 26.8% in the sublingual group. But here’s what’s really important… the babies did just fine. There was no difference in how many infants needed treatment for withdrawal symptoms (about 30% in the extended-release group vs 26.5% in the sublingual group), and the number of treatment days was similar too. So moms got better outcomes without putting their babies at extra risk.
The postpartum period told a different story, though. After delivery, both groups saw their abstinence rates drop to around 60%, and the advantage of extended-release buprenorphine basically disappeared. Women could switch to a monthly injection if they weren’t breastfeeding, but the protection that weekly shots provided during pregnancy didn’t carry over. This suggests that the postpartum period is just… harder. Life with a newborn, changing hormones, sleep deprivation, the stress of new motherhood – all of it creates challenges that medication alone can’t fully address. The study completion rate dropped from 98% during pregnancy to 81% at the 12-month mark, suggesting how difficult that first year can be.
One unexpected finding that deserves attention – babies exposed to extended-release buprenorphine had slightly larger head circumferences at birth (34.0 cm vs 33.4 cm). The researchers don’t make a big deal out of this, and it’s within normal range, but it’s the kind of detail that matters when you’re talking about medication during pregnancy. The extended-release group also had more side effects that doctors thought were related to the medication during pregnancy (26.1% vs 7.0%), though these weren’t serious ones. Injection site reactions were tracked carefully – because yeah, weekly shots can cause irritation – but they were generally mild and resolved quickly. What this all means is that extended-release buprenorphine isn’t perfect, but the trade-offs seem worth it for many pregnant women trying to stay in recovery.
How the researchers set this whole thing up
Who actually participated in the trial
You might be wondering who exactly signed up for this study. The research team enrolled pregnant women aged 18 to 41 years old, with an average age of 31.2, all dealing with moderate to severe opioid use disorder. These weren’t just any pregnancies – participants had to have singleton pregnancies (meaning one baby, not twins or more) and be somewhere between 6 to 30 weeks along when they joined.
Demographics tell an important story here. Of the participants, 116 were White, 10 were Black, and 10 were Hispanic. That’s a pretty significant racial disparity you can’t ignore when considering who gets access to these trials and what the results might mean for different communities.
Hospital requirements like rooming-in and NOWS protocols
Hospitals participating in this trial had to follow specific protocols for managing newborns at risk for withdrawal. Rooming-in practices were required, meaning babies stayed with their mothers rather than being whisked away to a separate nursery. Each facility also needed established NOWS (Neonatal Opioid Withdrawal Syndrome) assessment protocols to monitor infants for signs of withdrawal.
These standardised hospital requirements weren’t just bureaucratic checkbox items – they actually matter a lot for outcomes. When you keep mothers and babies together through rooming-in, it supports breastfeeding and bonding while also helping to naturally soothe withdrawal symptoms. The NOWS protocols ensured that every baby was evaluated consistently using validated scoring systems, allowing researchers to compare apples to apples across different hospital sites. Without these requirements, you’d end up with messy data in which differences in outcomes might reflect different hospital practices rather than the actual medications being studied.
The real deal on abstinence during pregnancy
You’re probably wondering which treatment actually keeps pregnant women off illicit opioids more effectively. The numbers tell a pretty clear story here. With a 98% completion rate through pregnancy, the extended-release group demonstrated superior illicit opioid abstinence compared to the standard sublingual approach. This wasn’t just a marginal difference either – we’re talking about real, measurable outcomes that matter for both mothers and babies.
Weekly urine samples don’t lie, and they painted a consistent picture throughout the study period. The data were collected systematically, tested against a 0.15 noninferiority margin to ensure statistical validity. What you need to know is that staying in treatment and staying abstinent are two different things, and this trial measured both with precision.
Comparing the abstinence rates side-by-side
Breaking down the actual percentages shows you exactly what we’re dealing with. The extended-release formulation achieved 82.5% abstinence from illicit opioids, while sublingual users hit 72.6%. That’s nearly a 10-point difference when you’re looking at outcomes that directly affect pregnancy health.
Proving superiority over the standard of care
The trial wasn’t designed just to show that extended-release was “as good as” sublingual treatment. It actually demonstrated superiority based on that 0.15 noninferiority margin they established. When you’re treating opioid use disorder during pregnancy, superior abstinence rates translate directly into better outcomes for developing babies and their mothers.
Statistical superiority means the difference wasn’t just chance or random variation. Both groups maintained that impressive 98% completion rate, so you can’t attribute the abstinence difference to people dropping out of one arm versus the other. The extended-release formulation simply performed better at keeping participants abstinent from illicit opioids throughout their pregnancies, measured week after week through objective urine testing.
What happens after the baby is born?
Postpartum abstinence and participant retention
Your recovery journey doesn’t end at delivery – and the data shows this phase brings real challenges. Postpartum abstinence rates declined for both treatment groups to 60.2% for extended-release and 59.5% for sublingual, revealing that the months after birth require just as much support as pregnancy itself. The numbers tell an interesting story: both formulations performed nearly identically during this critical period, which might surprise you if you expected one to clearly outperform the other.
Retention through the full year proved difficult, with 114 participants completing the entire 12-month study period after switching to the optional monthly dosing schedule. You can learn more about the complete trial findings in this Extended-Release vs Sublingual Buprenorphine in Pregnancy study. The postpartum period brings unique stressors – sleepless nights, hormonal shifts, new responsibilities – that can make staying in treatment harder than during pregnancy.
Moving from weekly to monthly dosing options
Participants had the option to switch from their assigned treatment to monthly extended-release dosing after delivery, which significantly altered the study dynamics. This flexibility recognises that your needs as a new parent differ dramatically from those during pregnancy – fewer clinic visits mean more time with your baby and less disruption to the establishment of new routines. The 114 women who made it through the full year did so under this modified monthly schedule, suggesting that reducing visit frequency might help with long-term retention when you’re juggling infant care.
Monthly dosing eliminates the daily medication routine that can feel overwhelming when you’re already managing feeding schedules, diaper changes, and sleep deprivation. But here’s what the researchers found: even with this convenience factor built in, abstinence rates still dropped compared to pregnancy outcomes. It shows that medication format alone isn’t the whole answer – you need comprehensive support that addresses the unique challenges of early motherhood, not just a different delivery method for the same medication.
Let’s talk about side effects and safety
Your choice between these two medications involves weighing different types of risks. Extended-release buprenorphine showed significantly lower serious adverse events during pregnancy at just 8.7% and postpartum at 6.0% – that’s really good news for major complications. But here’s the trade-off you need to know about: medication-related nonserious events were actually higher with the injection, coming in at 26.1% compared to only 7.0% for sublingual.
Tracking serious maternal complications
Serious complications are what you really worry about during pregnancy, right? The data here is pretty clear. Women using the extended-release injection experienced fewer serious adverse events – we’re talking about the kind of stuff that requires hospitalisation or poses real danger. The numbers drop even further postpartum to 6.0%, suggesting the injection might offer better protection when it matters most.
Dealing with injection site reactions and minor issues
So what’s behind that higher nonserious event rate of 26.1%? Most of these issues relate directly to getting a monthly injection – think soreness, redness, or swelling where you got the shot. These aren’t dangerous, but they’re definitely annoying and something you’ll deal with regularly. Compare that to the 7.0% rate with sublingual, where you’re just dissolving a film under your tongue daily.
Injection site reactions can range from mild tenderness that lasts a day or two to more persistent bruising or hardness at the injection spot. Some women rotate injection sites to minimise discomfort, but you’re still looking at a monthly reminder that comes with physical side effects. The good news? These reactions rarely require treatment beyond ice packs or over-the-counter pain relief, and they don’t put you or your baby at risk.
How the little ones actually fared
Neonatal opioid withdrawal syndrome results
You’ll be relieved to know that when researchers compared the babies, there was no significant difference in NOWS treatment needs between the two groups. Infants born to mothers on extended-release buprenorphine required treatment 30.2% of the time, while those whose mothers took sublingual medication needed treatment 26.5% of the time. The mean treatment days also showed no meaningful gap – 10.9 days versus 14.8 days, respectively.
Checking in on infant head circumference and growth
One small difference did emerge when measuring the newborns. Babies whose mothers received extended-release buprenorphine had a slightly larger mean head circumference (34.0 cm) than those in the sublingual group. Head circumference matters because it’s one of the key indicators doctors use to assess infant brain development and overall health in those first critical weeks of life.
Growth measurements in newborns tell you a lot about how well they developed in utero, and head size specifically can signal neurological development. The difference found here was modest, but it’s the kind of detail that helps your healthcare team understand the full picture of how different medication formulations might affect pregnancy outcomes. Both groups fell within normal ranges, which is what really matters when evaluating the safety profile of these treatments.
FAQ
Q: What makes extended-release buprenorphine different from the sublingual version for treating opioid use disorder during pregnancy?
A: The main difference comes down to how often you need to take the medication and how it’s delivered. Sublingual buprenorphine is a film or tablet you dissolve under your tongue every single day, while extended-release buprenorphine is given as a weekly injection under the skin during pregnancy. This study used a formulation called CAM2038, which is specifically designed to release the medication slowly over time.
The extended-release version addresses some real problems with the daily sublingual form. You don’t have to remember to take something every day, which can be tough when you’re dealing with pregnancy symptoms and everything else going on in life. There’s also less risk of the medication being diverted or misused since it’s administered by a healthcare provider. And here’s something interesting – the daily sublingual form creates these peaks and troughs in your system throughout the day, which can leave some pregnant women dealing with cravings or withdrawal symptoms between doses. The extended-release version keeps medication levels more stable.
But there was a concern going into this trial. Extended-release buprenorphine actually results in higher overall exposure to the medication compared to similar doses of the sublingual form. That means the developing baby gets exposed to more buprenorphine, too. The big question was whether this would lead to worse outcomes for newborns, particularly more severe withdrawal symptoms after birth.
Q: What did this clinical trial actually find out about safety and effectiveness for moms and babies?
A: The results were pretty compelling, especially for the pregnancy period. Women who received the weekly extended-release injections had significantly better outcomes in staying away from illicit opioids during pregnancy – 82.5% of their urine samples tested negative for illicit opioids compared to 72.6% for the sublingual group. That’s almost a 10-percentage-point difference, which is statistically significant.
The safety profile showed some interesting patterns. Women on extended-release buprenorphine had fewer serious adverse events during both pregnancy (8.7% vs 26.8%) and after delivery (6.0% vs 18.6%). That’s a big difference and really important for maternal health. However, more of the non-serious side effects in the extended-release group were considered related to the medication itself during pregnancy (26.1% vs 7.0%). This makes sense when you think about it – injection site reactions were common, though most were mild and resolved within a few days.
For the babies, the good news is that there wasn’t a significant difference in neonatal opioid withdrawal syndrome outcomes between the two groups. About 30% of babies in the extended-release group needed medication treatment for withdrawal compared to 26.5% in the sublingual group – not a statistically significant difference. The number of days babies needed treatment was also similar. One unexpected finding was that babies exposed to extended-release buprenorphine had slightly larger head circumferences at birth (34.0 cm vs 33.4 cm), though the clinical significance of this is unclear.
Q: Does the extended-release version work as well after the baby is born, and what happened with study participation?
A: Here’s where things get real – the postpartum period was a different story. After delivery, the effectiveness advantage of extended-release buprenorphine basically disappeared. Both groups had similar rates of staying away from illicit opioids (around 60% for both), and those rates dropped compared to during pregnancy. This decline happened across the board and shows just how challenging the postpartum period can be for women in recovery.
The study design changed a bit after delivery, too. Women who weren’t breastfeeding could switch to a monthly extended-release formulation instead of weekly injections, which gave them more flexibility. But the key takeaway is that neither form of buprenorphine seemed to have an edge during this vulnerable time after birth.
Participation rates were actually really impressive for this type of study. Out of 140 women who were randomised, 98% completed the study through pregnancy – that’s 137 participants. Only 2 people dropped out before delivery, which is remarkable. The completion rate through the full 12 months postpartum was 81% (114 participants), which is still quite good for a
